QuidelOrtho slashes 2026 outlook on China and respiratory weakness
2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.
The guidance cut is the single biggest new force pushing QDEL down this period.
China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.
These are the specific demand problems management blamed for the guidance cut.
Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.
It shows how professional valuations were reset lower after the guidance cut.
Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.
It is the main potential upside counterweight to the weak guidance.